SCHEMBL354430

SCHEMBL354430

O=C(O)c1ccccc1Nc1ccc(F)cc1

nearest known ligand 0.71

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FABP4 P15090 2/20 0.71
CDC7 O00311 2/20 0.69
DAPK3 O43293 1/20 0.69
PAK4 O96013 1/20 0.69
PIM1 P11309 1/20 0.69
CDK2 P24941 1/20 0.69
FLT3 P36888 1/20 0.69
GSK3B P49841 1/20 0.69
CDK9 P50750 1/20 0.69
CDK5 Q00535 1/20 0.69
DYRK1A Q13627 1/20 0.69
MELK Q14680 1/20 0.69
MINK1 Q8N4C8 1/20 0.69
HIPK2 Q9H2X6 1/20 0.69
STK17A Q9UEE5 1/20 0.69
PTGS1 P23219 2/20 0.69
AKR1C3 P42330 2/20 0.69
AKR1C2 P52895 2/20 0.69
MAPK8 P45983 2/20 0.64
MAPT P10636 3/20 0.63

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30294594 1.00 FABP4 (0.71) FABP4CDC7DAPK3PAK4PIM1
SCHEMBL22453647 0.94 FABP4 (0.63) FABP4CDC7DAPK3PAK4PIM1
SCHEMBL18109767 0.91 FABP4 (0.85) FABP4CDC7DAPK3PAK4PIM1
SCHEMBL7841736 0.87 FABP4 (0.85) FABP4PTGS1AKR1C3AKR1C2MAPK8
Fenamic Acid SCHEMBL29622832 0.87 FABP4 (0.92) FABP4PTGS1AKR1C3AKR1C2MAPK8
Fenamic Acid SCHEMBL25828 0.87 FABP4 (0.92) FABP4PTGS1AKR1C3AKR1C2MAPK8
Fenamic Acid SCHEMBL11800213 0.85 FABP4 (0.89) FABP4PTGS1AKR1C3AKR1C2MAPK8
Fenamic Acid SCHEMBL3657701 0.85 FABP4 (0.89) FABP4PTGS1AKR1C3AKR1C2MAPK8
Fenamic Acid SCHEMBL28520019 0.85 FABP4 (0.89) FABP4PTGS1AKR1C3AKR1C2MAPK8
Fenamic Acid SCHEMBL10800939 0.85 FABP4 (0.89) FABP4PTGS1AKR1C3AKR1C2MAPK8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-116813938-A Conjugated small molecule modified hydrogel and preparation method thereof 金陵科技学院 2023-09-29 CN disclosed
CN-113683615-A Evodiamine derivative and preparation and application thereof 南华大学 2021-11-23 CN disclosed
WO-2020261114-A1 2,3-DIHYDROQUINAZOLIN COMPOUNDS AS NAV1.8 INHIBITORS GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2020-12-30 WO disclosed
CN-110229114-A Remove C2-symmetric diphenylamine type chiral bisoxazoline ligand and synthetic method and application thereof 浙江工业大学 2019-09-13 CN disclosed
US-9126935-B2 Aurora kinase modulators and methods of use AMGEN INC. (US) 2015-09-08 US disclosed
US-9126935-B2 Aurora kinase modulators and methods of use AMGEN INC. (US) 2015-09-08 US disclosed
US-9126935-B2 Aurora kinase modulators and methods of use AMGEN INC. (US) 2015-09-08 US disclosed
US-20120015373-A1 ACRIDONE DERIVATIVES AS LABELS FOR FLUORESCENCE DETECTION OF TARGET MATERIALS GE HEALTHCARE UK LIMITED (GB) 2012-01-19 US disclosed
US-20110294837-A1 Aurora Kinase Modulators and Methods of Use AMGEN INC. 2011-12-01 US disclosed
US-20110294837-A1 Aurora Kinase Modulators and Methods of Use AMGEN INC. 2011-12-01 US disclosed
US-20090155903-A1 PHARMACEUTICAL COMPOSITION AND METHOD MYRIAD GENETICS, INCORPORATED (US) 2009-06-18 US disclosed
US-20090131527-A1 NOVEL ANTHRANILIC ACID DERIVATIVES AND CHLORIDE CHANNEL BLOCKING AGENT CONTAINING THE SAME KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) 2009-05-21 US disclosed
US-20080139788-A1 ACRIDONE DERIVATIVES AS LABELS FOR FLUORESCENCE DETECTION OF TARGET MATERIALS GE HEALTHCARE UK LIMITED (GB) 2008-06-12 US disclosed
US-20070031854-A1 Novel 10,10'-substituted-9,9'-biacridilidine luminescent molecules their preparation and uses KATSILOMETES GEORGE W 2007-02-08 US disclosed
US-20040191792-A1 Acridone derivatives as labels for fluorescence detection of target materials GE HEALTHCARE UK LIMITED (GB) 2004-09-30 US disclosed
EP-1392776-A2 ACRIDONE DERIVATIVES AS LABELS FOR FLUORESCENCE DETECTION OF TARGET MATERIALS Amersham Biosciences UK Limited (GB) 2004-03-03 EP disclosed
WO-2002099424-A2 ACRIDONE DERIVATIVES AS LABELS FOR FLUORESCENCE DETECTION OF TARGET MATERIALS AMERSHAM BIOSCIENCES UK LIMITED (GB) 2002-12-12 WO disclosed
US-20020034828-A1 NOVEL 10,10'-SUBSTITUTED-9,9'-BIACRIDINE LUMINESCENT MOLECULES AND THEIR PREPARATION PIERCE CHEMICAL COMPANY 2002-03-21 US disclosed
EP-1026156-A2 Novel 10, 10'-substituted-9,9'-biacridine luminescent molecules and their preparation PIERCE CHEMICAL COMPANY (US) 2000-08-09 EP disclosed
US-4168312-A Quinolone derivatives MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) 1979-09-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090131527-A1 NOVEL ANTHRANILIC ACID DERIVATIVES AND CHLORIDE CHANNEL BLOCKING AGENT CONTAINING THE SAME CLIC1, ASIC1, CLIC4 FABP4 1600/4885CDC7 2731/4885DAPK3 2212/4885
US-20110294837-A1 Aurora Kinase Modulators and Methods of Use AURKC, AURKA, CDK1 FABP4 4681/4885CDC7 16/4885DAPK3 582/4885
US-20080139788-A1 ACRIDONE DERIVATIVES AS LABELS FOR FLUORESCENCE DETECTION OF TARGET MATERIALS ACR, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, ARSA FABP4 1977/4885CDC7 3359/4885DAPK3 1543/4885
US-20040191792-A1 Acridone derivatives as labels for fluorescence detection of target materials ACR, ARSA, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 FABP4 1027/4885CDC7 3981/4885DAPK3 2048/4885
US-20090155903-A1 PHARMACEUTICAL COMPOSITION AND METHOD APP, PSEN2, PSEN1 FABP4 3844/4885CDC7 4594/4885DAPK3 4410/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.